Clinical Trial Update: Intravenous Immunoglobulin (IVIG) for Resistant Neuropathic Pain [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating intravenous immunoglobulin (IVIG) for resistant neuropathic pain is noted, sponsored by the University of Calgary. The current…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuropathic Pain

Drugs mentioned

• Intravenous immunoglobulin (IVIG) (intravenous immunoglobulin)

Snippet

Sponsor: University of Calgary | Conditions: Neuropathic Pain | Phase 2 | Status: UNKNOWN